| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 5,138.0 | 5,065.0 |
| Gross profit | 3,428.0 | 3,542.0 |
| Profit before tax | 733.0 | 939.0 |
| Net income | 580.0 | 755.0 |
| EPS (diluted, $ a share) | $0.40 | $0.51 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -23.2% |
|---|---|
| Revenue, year on year | +1.4% |
| Gross margin | 66.7% |
| Operating margin | 16.1% |
10-Q filed with the SEC, NYSE: BSX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Boston Scientific Corp: key numbers
- Share price
- $43.69Close, Nov 16
- Market cap
- $63.3B
- Shares outstanding
- 1.45BLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Boston Scientific Corp
All →Boston Scientific Executive Compensation
Boston Scientific's Board approved the 2027 Annual Bonus Plan, a cash incentive program for eligible employees and named executive officers based on global sales and adjusted EPS targets. The plan features a distribution percentage range of 0% to 150% and individual performance modifiers, allowing for a maximum payout of 225% of target bonus. The Board also approved the adoption of two new performance share programs for the 2027 performance year.
- Term
- 1 year
Boston Scientific Financial Results
Boston Scientific reported Q3 2026 net sales of $5.138 billion, representing 1.5% organic growth despite operational challenges from a previously disclosed cybersecurity incident. The company achieved GAAP EPS of $0.40 and adjusted EPS of $0.73, while continuing to advance its pipeline with new FDA clearances for its StoneSmart and SEISMIQ technologies.
“This has been a challenging year for Boston Scientific and I’m proud of how our global teams have responded, particularly to the cybersecurity incident, working with urgency and resilience to restore operations and continue supporting customers and patients. As we move forward, I remain confident in our long-term strategy, fueled by our dedicated talent, differentiated portfolio and strong pipeline of meaningful innovation.”
Mike Mahoney, chairman and chief executive officer, Boston Scientific
Boston Scientific Executive Compensation
Boston Scientific promoted Joe Fitzgerald to Executive Vice President and Chief Operating Officer, effective January 1, 2027. The company disclosed his new compensation package, including a $1.05 million base salary, a 110% target bonus, and a 2027 annual equity award valued at $7.0 million. The appointment coincides with a new operating structure consisting of three reportable segments: Interventional Therapies, Rhythm Solutions, and MedSurg.
Boston Scientific Leadership Change
Arthur C. Butcher, Executive Vice President and Group President of MedSurg and Asia Pacific, has announced his retirement effective January 1, 2027. He will serve as a senior advisor through February 26, 2027, maintaining his current annual base salary of $780,000 during the transition period.